Signaling Pathways in Cancer Pathogenesis and Therapy (Record no. 101018)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03269nam a22004335i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-1-4614-1216-8 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220083241.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 111111s2012 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781461412168 |
| -- | 978-1-4614-1216-8 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-1-4614-1216-8 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC261-271 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 614.5999 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Frank, David A. |
| Relator term | editor. |
| 245 10 - TITLE STATEMENT | |
| Title | Signaling Pathways in Cancer Pathogenesis and Therapy |
| Medium | [electronic resource] / |
| Statement of responsibility, etc | edited by David A. Frank. |
| 264 #1 - | |
| -- | New York, NY : |
| -- | Springer New York, |
| -- | 2012. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | VIII, 148 p. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Signaling Pathways in Cancer: 21st Century Approaches to Cancer Therapy -- Current And Next Generation Antimitotic Therapies In Cancer -- DNA Damage Checkpoint Signaling Pathways in Human Cancer -- Non-Receptor Tyrosine Kinases and their Roles in Cancer -- The Hedgehog Signaling Pathway in Cancer Pathogenesis and Therapy -- Wnt Signaling in Cancer Pathogenesis and Therapeutics -- STAT Signaling in the Pathogenesis and Treatment of Cancer -- Protein Therapeutics in Oncology.- Index . |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Since the 1940s, the treatment of advanced cancer has been based on administering maximal doses of non-specifically toxic drugs in the hope that cancer cells would be killed more effectively than normal cells. While this is occasionally successful, for most common cancers only a minority of patients experience any meaningful benefit. Unfortunately, nearly all treated patients experience toxicities, which range from unpleasant to life threatening. In recent years, however, our understanding of the molecular underpinnings of cancer has increased enormously. We now have a much deeper understanding of how intracellular signaling pathways that control critical cellular functions can become subverted by the genetic alterations arising in a cancer cell. In fact, we are now in a position to use this knowledge to design rational targeted therapeutic approaches that hold the promise of much greater efficacy with fewer side effects. In this volume, oncologists and scientists from academia, government, and industry have come together to provide insight into strategies to modulate signaling pathways, which are currently being translated from the laboratory to the clinic. These advances will hopefully usher in a new era in the treatment of cancer patients, and thus the goal of this volume is both to inform those interested in this field, and to inspire further contributions in this cutting edge area. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Toxicology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cancer Research. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacology/Toxicology. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9781461412151 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-1-4614-1216-8 |
| 912 ## - | |
| -- | ZDB-2-SBL |
No items available.